News
Tang Capital makes bid for 4th Bay Area biotech in 3 months, offering to take out Cargo Therapeutics
Kevin Tang's Concentra Biosciences lines up deal for flailing cancer cell therapy company Cargo Therapeutics — potentially ...
This approval targets the same indication that Summit Therapeutics’ ivonescimab will seek approval for based on its HARMONi clinical trial, according to Cantor Fitzgerald. The research firm views the ...
Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).
CRISPR Therapeutics’ CRSP first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications ...
NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results